abstract |
A novel 3-aryl-2-hydroxypropionic acid derivative, having formula (I) and pharmaceutically acceptable salts, solvates, and crystalline forms thereof, a process and intermediate for its manufacture, pharmaceutical preparations containing it and the use of the compound in clinical conditions associated with insulin resistance. |